CSPC Pharmaceutical Group (FRA:CVGU) ROCE %: 5.61% (As of Dec. 2025)


FRA:CVGU CSPC Pharmaceutical Group Ltd FRA:CVGU
88 GF Score
Price €2.58
GF Value €2.52
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group ROCE %?

CSPC Pharmaceutical Group FRA:CVGU -5.84% 88 ROCE % is 5.61% as of Dec. 2025. GuruFocus rates FRA:CVGU with a GF Score™ of 88/100 and a GF Value™ of €2.52. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CSPC Pharmaceutical Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 5.61%.

CSPC Pharmaceutical Group  (FRA:CVGU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CSPC Pharmaceutical Group ROCE % Related Terms

CSPC Pharmaceutical Group ROCE % Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group ROCE % Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.97 24.92 20.98 16.04 13.08

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.18 14.90 13.19 5.61 12.98
FRA:CVGU
88GF Score
CSPC Pharmaceutical Group Ltd FRA:CVGU
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group ROCE % Calculation

CSPC Pharmaceutical Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=587.672/( ( (5822.447 - 1263.683) + (5662.202 - 1234.084) )/ 2 )
=587.672/( (4558.764+4428.118)/ 2 )
=587.672/4493.441
=13.08 %

CSPC Pharmaceutical Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=248.492/( ( (0 - 0) + (5662.202 - 1234.084) )/ 1 )
=248.492/( ( 0 + 4428.118 )/ 1 )
=248.492/4428.118
=5.61 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.61% mean?
CSPC Pharmaceutical Group (FRA:CVGU) has a ROCE % of 5.61% as of Dec. 2025.
Is CSPC Pharmaceutical Group's ROCE % too high?
CSPC Pharmaceutical Group's current ROCE % is 5.61%. The Drug Manufacturers industry median ROCE % is 7.00. CSPC Pharmaceutical Group's value of 5.61% is 19.8% below this industry median. Overall, CSPC Pharmaceutical Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's ROCE % compare to LLY and JNJ?
CSPC Pharmaceutical Group's ROCE % of 5.61% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. CSPC Pharmaceutical Group's value of 5.61% is 19.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current ROCE % of 5.61% is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current ROCE % is 5.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (FRA:CVGU) has a current ROCE % of 5.61%. The stock's GF Value™ is €2.52, compared to a current price of €2.58 — trading 2.4% above its estimated fair value. The current ROCE % is 5.61% and 19.8% below the Drug Manufacturers industry median of 7.00. CSPC Pharmaceutical Group's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CSPC Pharmaceutical Group (FRA:CVGU), the current ROCE % is 5.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (FRA:CVGU) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of €2.58 is trading 2.4% above its estimated GF Value™ of €2.52.

Key valuation signals for FRA:CVGU:

  • ROCE %: 5.61%
  • GF Value™: €2.52 vs. price of €2.58 (2.4% above fair value)
  • GF Score™: 88/100 with 4 warning signs
  • Industry Position: 19.8% below the Drug Manufacturers median

No single metric tells the full story. See the FRA:CVGU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
88GF Score

Get the complete analysis for FRA:CVGU

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.58
Price
€2.52
GF Value